# ESBA1008 Safety, Tolerability and Effects in Wet Age-Related Macular Degeneration (AMD) Patients

> **NCT01304693** · PHASE1,PHASE2 · COMPLETED · sponsor: **Alcon Research** · enrollment: 376 (actual)

## Conditions studied

- Exudative Age-Related Macular Degeneration

## Interventions

- **BIOLOGICAL:** ESBA1008 solution
- **BIOLOGICAL:** Ranibizumab 0.5 mg

## Key facts

- **NCT ID:** NCT01304693
- **Lead sponsor:** Alcon Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 376 (ACTUAL)
- **Last updated:** 2014-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01304693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01304693, "ESBA1008 Safety, Tolerability and Effects in Wet Age-Related Macular Degeneration (AMD) Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01304693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*